Kurzfassung

A randomised, double-blind, Placebo-controlled, Phase § study to assess the efficacy and safety of Weekly farletuzumab (MORAb-003) in Combination with carboplatin and Taxane in Subjects with platinum-sensitive Ovarian Cancer in First Relapse